Royalty Pharma PLC (RPRX) intrinsic value & 10-year financials
Royalty Pharma PLC (RPRX) has a Graham intrinsic value of $31.97 per share. At $60.96 on Oct 17, 2026, the stock trades 91% above that value. Over the last 9 fiscal years revenue grew 4.1% a year to $2.4B, with an average return on invested capital of 10.2%.
- Graham intrinsic value
- $31.97
- Share price (Oct 17, 2026)
- $60.96
- Price vs Graham value
- 91% above
- Market cap
- $34.4B
- Revenue (FY2025)
- $2.4B
- Revenue growth (9-yr CAGR)
- 4.1%
- ROIC (10-yr avg)
- 10.2%
- Free cash flow (FY2025)
- —
RPRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $2.4B | $770.9M | $1.78 | — | 65.6% | 8.9% |
| FY2024 | $2.3B | $859.0M | $1.91 | — | 57.1% | 7.9% |
| FY2023 | $2.4B | $1.1B | $2.53 | — | 63.4% | 9.7% |
| FY2022 | $2.2B | $42.8M | $0.10 | — | 13.7% | 2.0% |
| FY2021 | $2.3B | $619.7M | $1.49 | — | 62.5% | 9.4% |
| FY2020 | $2.1B | $975.0M | $1.32 | — | 75.2% | 11.9% |
| FY2019 | $1.8B | $2.3B | — | — | 144.6% | 21.6% |
| FY2018 | $1.8B | $1.4B | — | — | 76.0% | — |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Royalty Pharma plc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Royalty Pharma plc returns on capital have been average, hovering around 10.2% ROIC over the decade.
Royalty Pharma plc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Royalty Pharma plc is modeled at 6.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $31.97 per share.